GPR35; DRD4; | |
TSHR; NPSR1; CXCR1; | |
RECQL; TDP1; PLA2G1B; APOBEC3G; P4HB; TERT; PKM; PIK3CG; PIK3R1; GLO1; HPGD; PGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; APEX1; POLB; CD38; | |
ACHE; GAA; | |
CFTR; | |
BCL2; | |
TOP2A; | |
NEK6; AKT1; MET; CAMK2B; GSK3B; CSNK2A1; DAPK1; SYK; NEK2; FLT3; MYLK; SRC; IGF1R; AURKB; DYRK1A; INSR; CDK6; CDK1; MAPK14; PIM1; NUAK1; ALK; PTK2; AXL; KDR; PKN1; | |
CA7; CA3; CA14; CA5B; CA5A; CA1; CA12; CA9; CA4; CA6; CA2; | |
AR; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; PTGS2; ALOX5; XDH; | |
MMP13; MMP12; MMP3; MMP2; MMP14; MMP9; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
DNMT1; | |
FUT7; | |
ABCC1; ABCB1; ABCG2; | |
LMNA; MAPT; THPO; NPC1; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP14 | Matrix metalloproteinase 14 | P50281 | CHEMBL3869 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.185E-12 | 5.630E-10 | APOBEC3G, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DNMT1, ESR1, ESR2, GLO1, L3MBTL1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PARP1, TNKS, TP53 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.927E-12 | 1.359E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.254E-12 | 1.815E-09 | AURKB, BCL2, CA2, CA7, CD38, CDK6, CFTR, HIF1A, KDR, MAPK14, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.933E-12 | 1.945E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.806E-11 | 3.641E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS2, SRC |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.299E-11 | 4.551E-09 | AKT1, AURKB, BCL2, CAMK2B, CDK1, DYRK1A, GSK3B, MAPK14, NEK6, PKN1, SRC, SYK, TNKS |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 3.102E-11 | 5.945E-09 | AKT1, ALK, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, DAPK1, DYRK1A, GSK3B, MAPK14, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, SYK |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 9.549E-11 | 1.563E-08 | AURKB, CA2, CA7, CFTR, HIF1A, MAPK14, NEK2, NPC1, NPSR1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.494E-10 | 3.824E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.033E-09 | 1.414E-07 | AKT1, BCL2, CAMK2B, CDK1, CSNK2A1, DYRK1A, GSK3B, PKN1, TNKS |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.279E-09 | 1.708E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.186E-09 | 2.690E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.027E-09 | 4.792E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.727E-09 | 6.669E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.365E-08 | 1.510E-06 | AKT1, BCL2, HIF1A, LMNA, P4HB, PTGS2, SRC, TERT, TP53 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.900E-08 | 2.028E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.098E-08 | 3.138E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.610E-07 | 2.160E-05 | ABCB1, CA2, CA7, CFTR |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.618E-07 | 2.160E-05 | HIF1A, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.923E-07 | 2.375E-05 | MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.655E-07 | 2.863E-05 | AXL, INSR, MET, NOX4, PIK3CG, PIK3R1, PTK2, SRC, THPO |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.806E-07 | 2.970E-05 | IGF1R, INSR, KDR, PTK2, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.096E-07 | 4.530E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 9.035E-07 | 6.451E-05 | HIF1A, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.837E-06 | 1.223E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.130E-06 | 1.393E-04 | AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, BCL2, CAMK2B, CDK1, CDK6, CSNK2A1, DNMT1, DYRK1A, ESR1, ESR2, GSK3B, HIF1A, HPGD, L3MBTL1, LMNA, MAPK14, NEK2, NEK6, NFKB1, NUAK1, PARP1, PIM1, PKN1, POLB, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TOP2A, TP53, USP2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.147E-06 | 1.395E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 2.562E-06 | 1.603E-04 | ALK, CDK1, DRD4, INSR, MAPK14, PKN1, PLA2G1B, SYK |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.679E-06 | 1.662E-04 | MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.863E-06 | 1.746E-04 | AURKB, NEK2, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.275E-06 | 2.509E-04 | CYP1A1, CYP2C8, CYP3A4 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 4.873E-06 | 2.830E-04 | AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AR, AURKB, BCL2, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, LMNA, MAPK14, MAPT, MMP14, MYLK, NEK2, NEK6, NFKB1, PGD, PIK3CG, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PYGL, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, XDH |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.896E-06 | 2.836E-04 | AXL, KDR, MAPK14, PIK3R1, PTK2, SRC |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 5.992E-06 | 3.434E-04 | AKT1, INSR, MAPK14, PIK3R1, TERT |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 6.728E-06 | 3.786E-04 | AKT1, HIF1A, KDR, MAPK14, PTGS2 |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 7.448E-06 | 4.148E-04 | ABCB1, ABCC1, ABCG2 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 8.416E-06 | 4.570E-04 | MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 8.596E-06 | 4.645E-04 | HPGD, MMP2, MMP9, TERT |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 9.007E-06 | 4.854E-04 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 9.347E-06 | 5.011E-04 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, PARP1, SRC, TP53 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.187E-05 | 6.156E-04 | AKT1, AURKB, CSNK2A1, DYRK1A, L3MBTL1, MAPK14, NUAK1, TP53 |
BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 1.275E-05 | 6.580E-04 | APEX1, APP, CFTR, NOX4, PIK3CG |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.324E-05 | 6.766E-04 | ACHE, CD38, CFTR, HIF1A, MAPK14, MMP12, PLA2G1B, SRC, SYK |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.375E-05 | 7.014E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.772E-05 | 8.748E-04 | INSR, KDR, SYK |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.867E-05 | 9.156E-04 | BCL2, NOX4, PARP1, POLB, TP53 |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.880E-05 | 9.199E-04 | AKT1, BCL2, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MMP9, NOX4, PTGS2, SRC, TOP2A, TP53, XDH |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 2.015E-05 | 9.749E-04 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 2.015E-05 | 9.749E-04 | APP, GSK3B, IGF1R, PARP1 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 2.339E-05 | 1.120E-03 | AKT1, BCL2, MAPT, TP53 |
MF | Unclassified; | GO:0032403; protein complex binding | 2.413E-05 | 1.150E-03 | ACHE, APEX1, FLT3, IGF1R, INSR, KDR, MMP12, MMP13, MMP14, MMP9, P4HB, PIK3R1, PKM, SRC, SYK, TSHR |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.432E-05 | 1.156E-03 | AKT1, BCL2, HIF1A, MMP9, PTGS2, SRC |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 2.520E-05 | 1.190E-03 | ABCB1, ABCC1, ABCG2 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 2.660E-05 | 1.248E-03 | AKR1B1, AKT1, CD38, DNMT1, HSD17B2, KDR, MMP2, PTGS2, SRC, TP53 |
MF | Unclassified; | GO:0140097; catalytic activity, acting on DNA | 2.680E-05 | 1.255E-03 | APEX1, DNMT1, PARP1, POLB, RECQL, TDP1, TERT, TOP2A |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.701E-05 | 1.262E-03 | AXL, IGF1R, INSR, PIK3R1 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 2.903E-05 | 1.345E-03 | APP, CDK1, MAPK14, PARP1, PIK3R1, PTGS2 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 2.940E-05 | 1.359E-03 | AKT1, APEX1, BCL2, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, ESR2, GSK3B, HSD17B10, MAOA, MAPK14, MMP2, MPO, NFKB1, NOX4, PARP1, PKM, SRC, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 3.449E-05 | 1.562E-03 | AR, CYP19A1, ESR1 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 3.449E-05 | 1.562E-03 | IGF1R, INSR, PIK3R1 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 3.622E-05 | 1.610E-03 | AKR1B1, APEX1, BCL2, GAA, HIF1A, NOX4, PARP1, SRC, TERT |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.638E-05 | 1.610E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.638E-05 | 1.610E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.638E-05 | 1.610E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.638E-05 | 1.610E-03 | ALOX12, ALOX15 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.947E-05 | 1.736E-03 | BCL2, CA2, CA7, KDR, NPSR1, PARP1, PLA2G1B, SRC |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.033E-05 | 1.767E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 4.082E-05 | 1.785E-03 | AKR1B1, AKT1, ALDH1A1, FUT7, GAA, MAPK14, PKM |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 4.819E-05 | 2.062E-03 | AXL, CYP1A1, CYP1A2, HPGD, MAPK14, MPO, NFKB1, PTGS2, SRC |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 5.152E-05 | 2.187E-03 | AURKB, NEK2, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 5.569E-05 | 2.341E-03 | AKT1, AXL, PIK3CG, PIK3R1, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 5.752E-05 | 2.409E-03 | AKT1, HIF1A, INSR, NFKB1, SRC |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 5.926E-05 | 2.467E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 6.484E-05 | 2.649E-03 | BCL2, NOX4, SRC, TERT |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 6.484E-05 | 2.649E-03 | CA2, CD38, SRC, SYK |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 7.139E-05 | 2.889E-03 | MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 7.236E-05 | 2.912E-03 | ESR1, NEK6, TERT, TP53 |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 7.509E-05 | 2.995E-03 | CYP19A1, ESR1, SRC |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 9.150E-05 | 3.558E-03 | ABCG2, ACHE, AKT1, APOBEC3G, BCL2, CAMK2B, FLT3, HPGD, MAPT, NFKB1, PTGS2, PYGL, TERT, TOP2A, XDH |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 9.345E-05 | 3.610E-03 | TERT, TNKS, TNKS2 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.810E-05 | 3.754E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 9.873E-05 | 3.772E-03 | CYP1B1, PIK3CG, PTK2, SYK |
BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 1.087E-04 | 4.088E-03 | ABCB1, ABCC1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.087E-04 | 4.088E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.087E-04 | 4.088E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.087E-04 | 4.088E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.087E-04 | 4.088E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.087E-04 | 4.088E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 1.145E-04 | 4.233E-03 | BCL2, PTK2, SRC |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 1.198E-04 | 4.392E-03 | AKT1, AURKB, DYRK1A, MAPK14 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.328E-04 | 4.836E-03 | AKR1B1, AKT1, AR, CFTR, SRC |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.384E-04 | 5.007E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.384E-04 | 5.007E-03 | AURKB, CDK1, PKN1 |
BP | GO:0032502; developmental process | GO:0022603; regulation of anatomical structure morphogenesis | 1.457E-04 | 5.221E-03 | ALOX12, AR, BCL2, CAMK2B, CYP1B1, ESR1, HIF1A, KDR, MAPK14, MAPT, PIM1, PKN1, PTGS2, PTK2, SRC, TERT, XDH |
CC | GO:0043226; organelle | GO:0000784; nuclear chromosome, telomeric region | 1.466E-04 | 5.242E-03 | APEX1, CDK1, PARP1, TERT, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.573E-04 | 5.595E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 1.654E-04 | 5.837E-03 | AKT1, HIF1A, TERT |
BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 1.866E-04 | 6.501E-03 | AKT1, MAPK14, MMP14, MPO, NFKB1, PTGS2, SRC |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.165E-04 | 7.390E-03 | TNKS, TNKS2 |
BP | GO:0051179; localization | GO:1901529; positive regulation of anion channel activity | 2.165E-04 | 7.390E-03 | ABCB1, CFTR |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.165E-04 | 7.390E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.165E-04 | 7.390E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 2.165E-04 | 7.390E-03 | APP, INSR |
MF | GO:0005488; binding | GO:0005497; androgen binding | 2.165E-04 | 7.390E-03 | ALDH1A1, AR |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 2.339E-04 | 7.859E-03 | APEX1, AR, CDK1, DNMT1, ESR1, L3MBTL1, MPO, NFKB1, PKN1, TOP2A, TP53 |
CC | Unclassified; | GO:0043234; protein complex | 2.376E-04 | 7.958E-03 | AKT1, ALK, APEX1, APOBEC3G, AR, AURKB, BCL2, CDK1, CDK6, CFTR, CSNK2A1, ESR1, FLT3, GSK3B, HIF1A, IGF1R, INSR, MAPT, NEK2, NEK6, NFKB1, P4HB, PARP1, PIK3R1, PKN1, POLB, PTGS2, SMN1, SMN2, SRC, SYK, TNKS, TOP2A, TP53, TTR |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 2.453E-04 | 8.166E-03 | BCL2, CD38, PARP1, SRC, TNKS, TNKS2 |
MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 2.565E-04 | 8.500E-03 | DYRK1A, PTK2, SRC, SYK |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 2.660E-04 | 8.710E-03 | CA2, PTGS2, SRC |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.660E-04 | 8.710E-03 | CYP1A1, POLB, TP53 |
BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 2.741E-04 | 8.936E-03 | ACHE, HSD17B10, IGF1R, INSR, PKM, TP53 |
BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 2.793E-04 | 9.077E-03 | AKR1B1, ALDH1A1, APP, CFTR, CYP1B1, CYP3A4, NPC1, TTR |
BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 2.808E-04 | 9.086E-03 | AURKB, CSNK2A1, NEK2, NEK6, TNKS |
BP | GO:0032502; developmental process | GO:0022612; gland morphogenesis | 3.067E-04 | 9.706E-03 | BCL2, POLB, STAT6 |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 3.067E-04 | 9.706E-03 | HIF1A, TERT, TP53 |
BP | GO:0008152; metabolic process | GO:0019637; organophosphate metabolic process | 3.120E-04 | 9.860E-03 | ACHE, ALDH1A1, ALOX15, CD38, CSNK2A1, MET, PARP1, PGD, PIK3CG, PIK3R1, PKM, PLA2G1B, PTGS2, PYGL, XDH |
BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 3.159E-04 | 9.946E-03 | AKT1, ALOX15, AXL, CXCR1, NFKB1, NOX4, PIK3CG, POLB, PTGS2, SYK |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.327E-22 | 1.207E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.451E-17 | 2.669E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.000E-14 | 4.537E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.749E-13 | 5.363E-11 | ABCB1, ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, DAPK1, DYRK1A, FLT3, GSK3B, IGF1R, INSR, KDR, MAPK14, MET, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TOP2A, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.038E-21 | 3.954E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.459E-13 | 9.175E-11 | CAMK2B; SRC; MMP2; PIK3R1; MAPK14; HIF1A; ESR1; MMP9; PTK2; PIK3CG; IGF1R; KDR; AKT1; TP53; MET |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.723E-11 | 8.355E-10 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PIK3CG; PTK2; IGF1R; AR; CDK6; BCL2; AKT1; MET; TP53 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.203E-11 | 7.780E-10 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.672E-10 | 1.187E-08 | GSK3B; SRC; AKT1; PIK3R1; MAPK14; ESR1; NFKB1; ESR2; PIK3CG |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.445E-09 | 4.004E-08 | GSK3B; SYK; INSR; PIK3R1; PTK2; NFKB1; PIK3CG; IGF1R; CDK6; KDR; BCL2; AKT1; PKN1; TP53; MET |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.462E-09 | 4.451E-08 | GSK3B; SYK; CSNK2A1; BCL2; CDK1; AKT1; CD38; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.449E-09 | 4.451E-08 | SRC; KDR; AKT1; PIK3R1; MAPK14; PTGS2; PTK2; PIK3CG |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.853E-09 | 4.451E-08 | CDK6; BCL2; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2; PIK3CG |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.524E-09 | 4.451E-08 | GSK3B; AR; BCL2; AKT1; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.744E-10 | 1.065E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.367E-09 | 1.211E-07 | DNMT1; PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; FUT7; HSD17B1; ALOX5; HSD17B2; CD38; XDH; GAA; PGD; CYP2C9; CYP2C8; PKM; CYP1A2; ALDH1A1; CYP1A1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.798E-09 | 4.523E-08 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.268E-09 | 7.861E-08 | PKM; FLT3; AKT1; PIK3R1; TP53; MET; HIF1A; PIK3CG |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.444E-08 | 1.751E-07 | CDK6; SRC; BCL2; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1; PIK3CG |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.309E-09 | 1.211E-07 | CAMK2B; INSR; BCL2; AKT1; PIK3R1; HIF1A; NFKB1; PIK3CG; IGF1R |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.665E-08 | 1.900E-07 | MMP14; MMP3; AKT1; PIK3R1; MAPK14; PTGS2; MMP9; NFKB1; PIK3CG |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.951E-08 | 2.102E-07 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.898E-08 | 2.811E-07 | GSK3B; SRC; KDR; BCL2; AKT1; PIK3R1; MET; PTK2; PIK3CG; MYLK; IGF1R |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.570E-08 | 3.298E-07 | CAMK2B; GSK3B; BCL2; AKT1; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.384E-07 | 1.033E-06 | MMP2; PIM1; BCL2; AKT1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.029E-07 | 8.523E-07 | CAMK2B; CDK6; AKT1; PIK3R1; TP53; PIK3CG; IGF1R |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.676E-08 | 2.733E-07 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.761E-07 | 1.266E-06 | DNMT1; ABCC1; CDK6; ABCB1; PIM1; BCL2; CYP1B1; PTGS2; TP53; MMP9; MET; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.184E-07 | 9.186E-07 | SRC; MMP2; AKT1; PIK3R1; ESR1; MMP9; ESR2; PIK3CG |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.054E-07 | 8.523E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.536E-07 | 2.365E-06 | POLB; CDK6; PKM; SYK; SRC; CDK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.910E-07 | 1.323E-06 | CDK6; AKT1; PIK3R1; TP53; MET; PIK3CG; IGF1R |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.613E-07 | 2.983E-06 | GSK3B; SRC; AKT1; PIK3R1; TP53; ESR1; HIF1A; PIK3CG |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.596E-08 | 4.053E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.248E-07 | 3.284E-06 | ABCC1; BCL2; AKT1; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.768E-07 | 4.710E-06 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2; PIK3CG |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.692E-06 | 8.419E-06 | PARP1; LMNA; BCL2; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.360E-06 | 7.131E-06 | GSK3B; CDK6; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.316E-06 | 7.090E-06 | INSR; AKT1; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.213E-06 | 1.798E-05 | SRC; INSR; KDR; AKT1; PIK3R1; MAPK14; MET; PIK3CG; IGF1R |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 9.010E-07 | 5.141E-06 | ALK; CDK6; AKT1; PIK3R1; TP53; PIK3CG |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.010E-07 | 5.141E-06 | INSR; AKT1; PIK3R1; PTGS2; TSHR; PIK3CG |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.564E-06 | 1.608E-05 | GSK3B; INSR; AKT1; PIK3R1; PYGL; NFKB1; PIK3CG |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.002E-06 | 5.555E-06 | FLT3; PIM1; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.618E-06 | 2.956E-05 | PLA2G1B; INSR; KDR; AKT1; PIK3R1; MET; NFKB1; PIK3CG; IGF1R |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 7.526E-06 | 2.956E-05 | SYK; SRC; AKT1; PIK3R1; MAPK14; PIK3CG; MYLK |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 6.038E-06 | 2.441E-05 | ALOX5; BCL2; AKT1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.658E-06 | 8.419E-06 | GSK3B; BCL2; AKT1; PIK3R1; TP53; PIK3CG |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.404E-06 | 1.138E-05 | CDK6; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.439E-05 | 5.265E-05 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.357E-06 | 1.798E-05 | GSK3B; SYK; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.326E-05 | 4.946E-05 | GSK3B; AKT1; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.196E-06 | 1.065E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.357E-06 | 1.798E-05 | CDK6; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.127E-06 | 1.444E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.029E-05 | 1.303E-04 | THPO; PIM1; BCL2; AKT1; STAT6; PIK3R1; PIK3CG |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.393E-05 | 8.289E-05 | CDK1; AKT1; PIK3R1; MAPK14; PIK3CG; IGF1R |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 4.029E-05 | 1.303E-04 | CAMK2B; SRC; CD38; PIK3R1; PTGS2; PIK3CG; MYLK |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 2.393E-05 | 8.289E-05 | CAMK2B; SRC; ALOX12; PIK3R1; MAPK14; PIK3CG |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.352E-05 | 1.141E-04 | GSK3B; AKT1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 4.839E-05 | 1.481E-04 | CAMK2B; ACHE; BCL2; AKT1; PIK3R1; PIK3CG |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.774E-05 | 6.374E-05 | SYK; CSNK2A1; PARP1; BCL2; PTGS2; NFKB1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 8.560E-05 | 2.394E-04 | CAMK2B; SYK; SRC; BCL2; AKT1; MAPK14; NFKB1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 6.813E-05 | 1.991E-04 | MMP2; PIK3R1; MAPK14; MMP9; PTK2; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.398E-04 | 3.521E-04 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 8.974E-05 | 2.452E-04 | INSR; AKT1; PIK3R1; CFTR; PIK3CG; IGF1R |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.116E-04 | 2.967E-04 | CAMK2B; GSK3B; MAOA; AKT1; MAPK14; DRD4 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.267E-04 | 3.277E-04 | SYK; AKT1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.711E-04 | 4.203E-04 | CAMK2B; AKT1; PIK3R1; CFTR; NFKB1; TSHR; PIK3CG |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.320E-04 | 3.371E-04 | INSR; AKT1; PIK3R1; MAPK14; PIK3CG; IGF1R |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.681E-04 | 4.181E-04 | GSK3B; INSR; AKT1; PIK3R1; PYGL; PIK3CG |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.888E-04 | 4.522E-04 | GSK3B; AKT1; PIK3R1; MAPK14; PIK3CG; IGF1R |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 4.884E-05 | 1.481E-04 | SYK; AKT1; PIK3R1; MAPK14; PIK3CG |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 3.640E-05 | 1.217E-04 | INSR; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.312E-05 | 4.946E-05 | GSK3B; AKT1; PIK3R1; TP53; PIK3CG |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.037E-04 | 4.762E-04 | SYK; CXCR1; INSR; AKT1; PIK3R1; PIK3CG |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.633E-04 | 6.010E-04 | GSK3B; INSR; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.363E-04 | 5.457E-04 | CAMK2B; BCL2; AKT1; PIK3R1; MAPK14; PIK3CG |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.227E-05 | 1.344E-04 | AKT1; PIK3R1; MET; HIF1A; PIK3CG |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.777E-04 | 1.245E-03 | GSK3B; AKT1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.818E-02 | 3.067E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 8.525E-03 | 1.531E-02 | SRC; PIK3R1; PTK2; PIK3CG; MYLK |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.985E-02 | 3.320E-02 | CXCR1; THPO; FLT3; KDR; MET |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.712E-02 | 2.913E-02 | AKT1; MAPT; MAPK14; TP53; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.981E-04 | 8.775E-04 | AKT1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.982E-06 | 1.756E-05 | DAPK1; SRC; MMP2; MMP9; TP53 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.340E-05 | 2.094E-04 | CSNK2A1; SRC; INSR; MET; IGF1R |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.020E-03 | 5.859E-03 | INSR; AKT1; PIK3R1; PIK3CG; MYLK |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.876E-05 | 1.991E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 4.884E-05 | 1.481E-04 | CXCR1; SRC; MAPK14; MET; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.016E-05 | 1.796E-04 | ABCB1; CA2; CYP3A4; CFTR; ABCG2 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.958E-04 | 4.633E-04 | CAMK2B; MMP14; SRC; MMP2; MAPK14 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.342E-02 | 3.850E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.098E-03 | 5.951E-03 | BACE1; APP; GSK3B; MAPT; HSD17B10 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.646E-04 | 8.130E-04 | AKT1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 9.442E-05 | 2.544E-04 | SRC; PIK3R1; MET; PTK2; PIK3CG |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.729E-03 | 1.716E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 5.919E-03 | 1.115E-02 | CAMK2B; AR; CDK1; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.089E-03 | 1.136E-02 | GSK3B; CDK6; CDK1; TP53 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.936E-03 | 5.754E-03 | AKT1; PIK3R1; HIF1A; PIK3CG |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.176E-03 | 4.491E-03 | SYK; AKT1; PIK3R1; PIK3CG |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.936E-03 | 5.754E-03 | CAMK2B; PKM; AKT1; PYGL |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.832E-03 | 5.665E-03 | PIK3R1; NFKB1; PTK2; PIK3CG |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.443E-03 | 4.936E-03 | CA2; PLA2G1B; CD38; CFTR |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.493E-02 | 2.564E-02 | THPO; FLT3; CD38 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.405E-02 | 2.433E-02 | PKN1; MAPK14; NFKB1 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 9.336E-04 | 1.975E-03 | CAMK2B; CA2; CFTR; MYLK |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 9.015E-03 | 1.604E-02 | MAPK14; PTGS2; NFKB1 |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 7.723E-03 | 1.413E-02 | CDK6; CDK1; TP53 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 6.548E-03 | 1.210E-02 | SRC; MAPK14; NFKB1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.213E-04 | 9.184E-04 | AKT1; PIK3R1; HIF1A; PIK3CG |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.971E-02 | 4.843E-02 | CYP3A4; XDH |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.312E-03 | 6.300E-03 | BCL2; MAPK14; TP53 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.774E-04 | 4.303E-04 | PKM; INSR; PIK3R1; PIK3CG |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.315E-03 | 4.727E-03 | AKT1; PIK3R1; PIK3CG |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.260E-04 | 3.277E-04 | ABCC1; ABCB1; CFTR; ABCG2 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.640E-05 | 2.394E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.290E-02 | 3.797E-02 | PKM; GLO1 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.529E-03 | 3.190E-03 | INSR; PIK3R1; PIK3CG |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.326E-02 | 2.318E-02 | GAA; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 9.366E-04 | 1.975E-03 | POLB; PARP1; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.922E-03 | 1.436E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.354E-04 | 7.567E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; TERT; CYP19A1; PIK3CG; FLT3; FLT3; CA9; IGF1R; INSR; KDR; KDR; KDR; CDK1; BCL2; ESR1; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; ESR1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; KDR; PARP1 |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; ABCB1; SYK; PIK3CG; FLT3; CA9; MMP2; MMP14; SRC; IGF1R; AURKB; HIF1A; KDR; KDR; KDR; MMP9; PTK2; TP53; TOP2A |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
NA: NA | Postmenopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; PIK3CG; KDR |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; PIK3CG; CYP2C9 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PIK3CG; PIK3CG; PTGS2; INSR; NFKB1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; GSK3B; CSNK2A1; ABCB1; SYK; PIK3CG; CA1; FLT3; FLT3; CA9; MMP2; ACHE; DNMT1; PTGS2; SRC; IGF1R; CD38; HIF1A; KDR; CDK1; MAPK14; MMP9; NFKB1; PIM1; PARP1; PTK2; BCL2; BCL2; TP53; ESR1; ESR1; APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; BCL2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; SRC; IGF1R; CD38; BCL2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; PIK3CG; PTGS2; PTGS2; ALOX5; MAPK14 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; PTK2; TP53 |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TERT; PIK3CG; FLT3; BCL2; ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; MMP12; MMP12; ALOX5; MAPK14 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; SYK; SYK; MMP12; PTGS2; ALOX5; ALOX5 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK; ALOX5 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; KDR; MMP9; TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; SYK; ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; ALOX5 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; DNMT1; KDR |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
NA: NA | Geographic retinal atrophy | NA | APP |
NA: NA | GIST | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; INSR; CDK1; ESR1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; CD38; AURKB; TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESR1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; ESR1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; ABCB1; MMP2; KDR; KDR; KDR; KDR; PARP1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; BCL2; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; ACHE; ACHE; ACHE; PTGS2; INSR; APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3; PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5; MAPK14; BCL2 |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
NA: NA | Inflammatory diseases | NA | MAPK14 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; CA9; INSR; HIF1A; BCL2 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; ALOX5 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; MMP13; SYK; PIK3CG; MMP12; PTGS2; ALOX5; MAPK14 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ALOX5 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; MAPK14 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
NA: NA | Angioedema | NA | PIK3CG |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; AXL; DNMT1; PTGS2; IGF1R; IGF1R; KDR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2; MYLK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; KDR; KDR; TP53 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ESR1; APP |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
NA: NA | Edema | NA | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; DNMT1; DNMT1; AURKB; TP53; TP53 |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; ALOX5; MAPK14 |
NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; MAPK14 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
NA: NA | Enthesopathy | NA | PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; SRC |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; KDR; APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; FLT3; MMP2; PTGS2; KDR |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
NA: NA | Male hypogonadism | NA | AR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |